Wyeth Pharmaceuticals, France’s Nautilus Biotech in hemophilia B tie-up (Sharewatch)
Wyeth Pharmaceuticals, France’s Nautilus Biotech in hemophilia B tie-up (Sharewatch)
These extended half-life proteins will be designed to enhance patient convenience as they will reduce the number and frequency of treatments needed. Nautilus Biotech will apply its proprietary technology to improve the duration of action of recombinant hemophilia B therapy.